Top of this page
Skip navigation, go straight to the content

UCB unveils new R&D partnership with Oxford University

  • Posted by

    We have recently announced a new collaboration with Oxford University to develop innovative research in immunology and neurology.

    The partnership will see UCB contribute £3.6 million (€4.3 million) over three years and gives scientists from our company and from Oxford University a chance to work together to find treatments for serious diseases. We expect this collaboration to be even greater than the sum of its parts.

    Teaming up with one of the world’s oldest and most prestigious universities combines our own world-class antibody research with Oxford’s academic excellence, and applies it to finding new solutions for patients.

    This new alliance has not happened in isolation. Regular readers will be aware of UCB’s commitment to R&D partnerships. For example, last year UCB joined forces with Harvard University to boost innovative research and drug discovery.

    More recently, our CEO, Dr Roch Doliveux, has been appointed to chair the Innovative Medicines Initiative (IMI) which is a major public-private partnership co-funded by industry and the European Union.

    We’ve even worked with Amgen and NASA on a truly out-of-this-world project.

    For all of us at UCB, partnerships with other companies, with academic and with patient groups are a source of pride as well as living demonstration of our commitment to open innovation.
  • Like